Addex terminates development of lead drug candidate for long-term migraine and GORD therapy
This article was originally published in Scrip
Executive Summary
A high incidence of liver function abnormalities in a Phase IIb anti-migraine trial has prompted Addex Pharmaceuticals to terminate the development of its lead candidate, ADX10059, for chronic migraine and gastro-oesophageal reflux disease (GORD) indications. The company's share price was down 70%, to CHF12.00 ($12.48), on the Swiss stock exchange, in early morning trading on December 16th.